303 related articles for article (PubMed ID: 9772876)
21. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
22. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
[TBL] [Abstract][Full Text] [Related]
23. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
24. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
Veltri RW; Miller MC
Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
[TBL] [Abstract][Full Text] [Related]
25. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
27. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
Patel D; White PA; Milford Ward A
BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
[TBL] [Abstract][Full Text] [Related]
28. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
29. The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation.
Klingler HC; Woo H; Rosario D; Cutinha PE; Anderson J; Ward AM; Chapple CR
Br J Urol; 1998 Sep; 82(3):393-7. PubMed ID: 9772877
[TBL] [Abstract][Full Text] [Related]
30. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED
Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107
[TBL] [Abstract][Full Text] [Related]
31. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
[TBL] [Abstract][Full Text] [Related]
32. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
33. Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.
Stimac G; Spajic B; Reljic A; Katusic J; Popovic A; Grubisic I; Tomas D
Korean J Urol; 2014 Aug; 55(8):527-32. PubMed ID: 25132947
[TBL] [Abstract][Full Text] [Related]
34. Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.
Pfister C; Basuyau JP;
World J Urol; 2005 Sep; 23(4):236-42. PubMed ID: 16096832
[TBL] [Abstract][Full Text] [Related]
35. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
36. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
37. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
[TBL] [Abstract][Full Text] [Related]
38. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
39. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
[TBL] [Abstract][Full Text] [Related]
40. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]